[Ketogenic diet: efficacy and tolerability in childhood intractable epilepsy]

R Caraballo1, J Trípoli, L Escobal

  • 1Servicio de Neurología, Hospital de Pediatría Juan P. Garraham, Buenos Aires, Argentina.

Revista De Neurologia
|April 9, 1998
PubMed

Insights

The ketogenic diet (KD) is effective for treating intractable epilepsies (IE) in children, with 50% of compliant patients showing significant seizure reduction and improved quality of life. This diet is generally well-tolerated by pediatric patients.

Area of Science:

  • Neurology
  • Pediatrics
  • Clinical Nutrition

Context:

  • Intractable epilepsies (IE) in children pose significant treatment challenges.
  • Antiepileptic drugs (AEDs) are often insufficient for managing severe pediatric epilepsy.
  • The ketogenic diet (KD) is an established alternative therapy for drug-resistant epilepsy.

Purpose:

  • To evaluate the efficacy and tolerability of the classic ketogenic diet (KD) in children with intractable epilepsies (IE).
  • To assess seizure frequency reduction and quality of life improvements in pediatric patients undergoing KD therapy.
  • To determine the feasibility and acceptance of KD by children and their families.

Summary:

  • Eighteen pediatric patients (ages 2-11) with intractable epilepsies were enrolled in a prospective study.
  • Nine patients (64%) achieved sustained ketosis and adherence to the KD for at least two months.
  • Of the compliant patients, 7 (50%) experienced a 50-75% reduction in seizures, and 4 (29%) had a 75-100% reduction.

Impact:

  • The ketogenic diet (KD) demonstrates significant potential in reducing seizure frequency in children with intractable epilepsies (IE).
  • KD therapy was well-tolerated by most pediatric patients and their families, improving quality of life.
  • Further research with larger cohorts and longer follow-up is needed to fully understand KD's long-term effects and syndrome-specific efficacy.
Abstract

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...